Pertussis- Pipeline Insight, 2025

This “Pertussis- Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Pertussis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Pertussis: Understanding

Pertussis: Overview

Pertussis, commonly known as whooping cough, is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. It primarily affects infants and young children, but can also occur in adolescents and adults. The disease is characterized by severe coughing spells that can last for weeks or even months. Despite the availability of vaccines, pertussis remains a significant public health issue due to periodic outbreaks and the waning immunity from vaccination over time. The clinical presentation of pertussis occurs in three stages. The first stage, known as the catarrhal stage, mimics a common cold with symptoms such as a runny nose, mild fever, and a mild cough. This stage lasts for 1-2 weeks. The second stage, called the paroxysmal stage, is marked by severe and rapid coughing fits that can end in a high-pitched 'whoop' sound when the person breathes in. This stage can last from 1-6 weeks, and the coughing fits can lead to vomiting, exhaustion, and complications such as pneumonia. The final stage, known as the convalescent stage, involves a gradual recovery, although the cough may persist for months.

Pertussis is caused by Bordetella pertussis, a Gram-negative coccobacillus. The bacteria attach to the cilia of the respiratory epithelial cells, producing toxins that paralyze the cilia and cause inflammation of the respiratory tract, which interferes with the clearing of pulmonary secretions. The pertussis toxin, in particular, plays a crucial role by increasing cyclic AMP in host cells, leading to various systemic effects. The bacterium spreads through respiratory droplets from coughs or sneezes of an infected person. Due to its high infectivity, pertussis can spread rapidly, especially in populations with low vaccination coverage.

Diagnosing pertussis can be challenging, particularly in the early stages when symptoms resemble those of other respiratory infections. Clinical diagnosis is often based on the characteristic whooping cough and history of exposure. Laboratory confirmation can be achieved through nasopharyngeal swabs, with polymerase chain reaction (PCR) being the most sensitive method. Culture of Bordetella pertussis is also used but is less sensitive and time-consuming. Serological tests can be helpful in certain cases, especially for detecting antibodies in later stages of the disease.

The primary treatment for pertussis involves antibiotics, with macrolides (such as azithromycin, clarithromycin, or erythromycin) being the drugs of choice. Early treatment can help reduce the severity and duration of symptoms and decrease the transmission of the disease. Supportive care, including hydration and oxygen therapy, may be necessary for severe cases, especially in infants. Prevention through vaccination is the most effective strategy against pertussis. The DTaP (diphtheria, tetanus, and acellular pertussis) vaccine is administered to children in a series of shots, while the Tdap booster is recommended for adolescents and adults. Pregnant women are also advised to receive the Tdap vaccine during each pregnancy to protect newborns. Despite vaccination efforts, monitoring and timely booster doses are crucial to maintain immunity within the community.

'Pertussis- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pertussis pipeline landscape is provided which includes the disease overview and Pertussis treatment guidelines. The assessment part of the report embraces, in depth Pertussis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pertussis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pertussis R&D. The therapies under development are focused on novel approaches to treat/improve Pertussis.

Pertussis Emerging Drugs Chapters

This segment of the Pertussis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pertussis Emerging Drugs

Diphtheria, tetanus and pertussis vaccine DTcP Infant: Tianjin CanSino Biotechnology

DTcP Infant is a potential best-in-class DTcP vaccine for infants for primary vaccination in China which is being developed by Tianjin CanSino Biotechnology. The manufacturing process of the co-purified diphtheria, tetanus and acellular pertussis vaccine (DTaP) currently available in China uses a process of co-purification of pertussis antigens. As a diphtheria, tetanus and acellular pertussis (components) vaccine, each pertussis antigen of the DTcP Infant can be purified separately and formulated in a defined ratio, thus ensuring batch-to-batch consistency of product quality and making the product more stable. As of the date of this report, no domestically manufactured component vaccine for diphtheria, tetanus and acellular pertussis has been approved for marketing in China. DTcP Infant is positioned as a viable alternative to imported vaccines in China. Furthermore, the development of DTcP Infant establishes a solid foundation for the further development of Tdcp Adolescent and Adult, as well as CS-2201 DTcP components combined vaccine. In August 2023, the phase III trial for DTcP Infant was officially initiated and the first trial patient case has been formally enrolled. The Company expects to commence pre-NDA process in 2025. Currently the drug is in Phase III stage of development for the treatment of pertussis.

BPZE1: ILiAD Biotechnologies

BPZE1 is a next-generation live-attenuated pertussis vaccine designed to induce comprehensive and durable protection against B. pertussis infection (colonization) and disease (whooping cough). BPZE1 is being developed to block B. pertussis from colonizing the nasal passages of adults and children, to protect adults and children from whooping cough, and to potentially prevent transmission, including transmission to infants. By blocking B. pertussis colonization in nasal passages, the vaccine may also prevent transmission, thereby reducing the incidence of pertussis disease. The designation is supported by data from 4 clinical trials evaluating BPZE1 in healthy adults. BPZE1 was developed at the Institut Pasteur de Lille (France) in the lab of Camille Locht PhD and Nathalie Mielcarek PhD. Currently, the drug is in Phase II stage of its development for the treatment of pertussis.

Pertussis: Therapeutic Assessment

This segment of the report provides insights about the different Pertussis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pertussis

• There are approx. 10+ key companies which are developing the therapies for Pertussis. The companies which have their Pertussis drug candidates in the most advanced stage, i.e. phase III include, Tianjin CanSino Biotechnology.

Phases

The report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pertussis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pertussis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pertussis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pertussis drugs.

Pertussis Report Insights

• Pertussis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pertussis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pertussis drugs?
• How many Pertussis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pertussis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pertussis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pertussis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tianjin CanSino Biotechnology
• ILiAD Biotechnologies
• LG Chem
• BioNet-Asia
• Intravacc
• VAXFORM LLC

Key Products

• Diphtheria, tetanus and pertussis vaccine DTcP Infant
• BPZE1
• LR19114
• Recombinant Tdap
• Avacc 3
• Oral DTaP Vaccine

This product will be delivered within 2 business days.